Becton, Dickinson and Company (NYSE:BDX), a leading player in the medical technology sector with a market capitalization of ...

Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $237.38 which represents a slight increase of $1.08 or 0.46% from the prior close of $236.3. The stock opened at $236.51 and ...

Becton, Dickinson and Company BDX, popularly known as BD ... The optimism led by a solid fourth-quarter fiscal 2024 performance and a few strategic deals are expected to contribute further.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.17% of ...

Becton, Dickinson and Company BDX, popularly known as BD ... The segment was aided by its IDS business unit, whose performance reflected strong growth in Specimen Management driven by broad ...

Barclays analyst Matt Miksic lowered the firm’s price target on Becton Dickinson (BDX) to $278 from $312 and keeps an Overweight rating on the ...

EVP Shana Carol Neal sold 788 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an ...

So we wouldn't blame long term Becton, Dickinson and Company (NYSE:BDX) shareholders for doubting ... have been the driver of long term performance, or if there are some discrepancies.